vs
Cellectis S.A.(CLLS)与Digimarc CORP(DMRC)财务数据对比。点击上方公司名可切换其他公司
Cellectis S.A.的季度营收约是Digimarc CORP的1.1倍($9.5M vs $8.9M),Digimarc CORP净利率更高(-47.2% vs -265.9%,领先218.7%),Cellectis S.A.同比增速更快(375.0% vs 2.9%),Cellectis S.A.自由现金流更多($27.6M vs $895.0K)
Cellectis S.A.是一家法国生物制药公司,专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术,目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构,在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
迪吉马克公司是一家企业软件与服务提供商,其主打产品包含带数字标识符的软件,主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯,产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CLLS vs DMRC — 直观对比
营收规模更大
CLLS
是对方的1.1倍
$8.9M
营收增速更快
CLLS
高出372.1%
2.9%
净利率更高
DMRC
高出218.7%
-265.9%
自由现金流更多
CLLS
多$26.7M
$895.0K
损益表 — Q2 FY2024 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $9.5M | $8.9M |
| 净利润 | $-25.3M | $-4.2M |
| 毛利率 | — | 63.5% |
| 营业利润率 | -181.1% | -48.2% |
| 净利率 | -265.9% | -47.2% |
| 营收同比 | 375.0% | 2.9% |
| 净利润同比 | -51.9% | 51.4% |
| 每股收益(稀释后) | $-0.28 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
CLLS
DMRC
| Q4 25 | — | $8.9M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | $9.5M | $10.4M | ||
| Q1 24 | — | $9.9M |
净利润
CLLS
DMRC
| Q4 25 | — | $-4.2M | ||
| Q3 25 | — | $-8.2M | ||
| Q2 25 | — | $-8.2M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | $-25.3M | $-9.3M | ||
| Q1 24 | — | $-10.3M |
毛利率
CLLS
DMRC
| Q4 25 | — | 63.5% | ||
| Q3 25 | — | 58.3% | ||
| Q2 25 | — | 58.8% | ||
| Q1 25 | — | 65.0% | ||
| Q4 24 | — | 60.8% | ||
| Q3 24 | — | 62.4% | ||
| Q2 24 | — | 66.1% | ||
| Q1 24 | — | 62.5% |
营业利润率
CLLS
DMRC
| Q4 25 | — | -48.2% | ||
| Q3 25 | — | -109.7% | ||
| Q2 25 | — | -105.2% | ||
| Q1 25 | — | -128.9% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -120.4% | ||
| Q2 24 | -181.1% | -96.2% | ||
| Q1 24 | — | -109.2% |
净利率
CLLS
DMRC
| Q4 25 | — | -47.2% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -102.6% | ||
| Q1 25 | — | -125.2% | ||
| Q4 24 | — | -99.9% | ||
| Q3 24 | — | -113.9% | ||
| Q2 24 | -265.9% | -89.3% | ||
| Q1 24 | — | -104.0% |
每股收益(稀释后)
CLLS
DMRC
| Q4 25 | — | $-0.18 | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $-0.55 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | — | $-0.50 | ||
| Q2 24 | $-0.28 | $-0.43 | ||
| Q1 24 | — | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $40.2M |
| 总资产 | $407.1M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
CLLS
DMRC
| Q4 25 | — | $12.9M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | — | $16.1M | ||
| Q1 25 | — | $21.6M | ||
| Q4 24 | — | $28.7M | ||
| Q3 24 | — | $33.7M | ||
| Q2 24 | $149.0M | $41.5M | ||
| Q1 24 | — | $48.9M |
股东权益
CLLS
DMRC
| Q4 25 | — | $40.2M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $46.5M | ||
| Q1 25 | — | $50.0M | ||
| Q4 24 | — | $61.4M | ||
| Q3 24 | — | $70.2M | ||
| Q2 24 | $148.6M | $77.2M | ||
| Q1 24 | — | $84.5M |
总资产
CLLS
DMRC
| Q4 25 | — | $53.0M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | $66.5M | ||
| Q4 24 | — | $75.8M | ||
| Q3 24 | — | $85.0M | ||
| Q2 24 | $407.1M | $93.4M | ||
| Q1 24 | — | $99.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $28.9M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $895.0K |
| 自由现金流率自由现金流/营收 | 290.5% | 10.0% |
| 资本支出强度资本支出/营收 | 13.2% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-12.3M |
8季度趋势,按日历期对齐
经营现金流
CLLS
DMRC
| Q4 25 | — | $991.0K | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-4.7M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-7.1M | ||
| Q2 24 | $28.9M | $-6.8M | ||
| Q1 24 | — | $-8.4M |
自由现金流
CLLS
DMRC
| Q4 25 | — | $895.0K | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | $27.6M | $-6.9M | ||
| Q1 24 | — | $-8.5M |
自由现金流率
CLLS
DMRC
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | -36.9% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -59.1% | ||
| Q4 24 | — | -49.1% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | 290.5% | -66.1% | ||
| Q1 24 | — | -85.8% |
资本支出强度
CLLS
DMRC
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | 13.2% | 0.3% | ||
| Q1 24 | — | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |